SKYE Stock Overview
A clinical stage biopharmaceutical company, discovers, develops, and commercializes therapeutic drugs that modulate the endocannabinoid system.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Skye Bioscience, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$10.48 |
| 52 Week High | US$19.41 |
| 52 Week Low | US$1.44 |
| Beta | 1.63 |
| 1 Month Change | -17.35% |
| 3 Month Change | -20.67% |
| 1 Year Change | 132.89% |
| 3 Year Change | -75.34% |
| 5 Year Change | -86.03% |
| Change since IPO | -99.58% |
Recent News & Updates
Recent updates
Shareholder Returns
| SKYE | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -4.2% | 0.02% | 1.2% |
| 1Y | 132.9% | 6.7% | 20.6% |
Return vs Industry: SKYE exceeded the US Biotechs industry which returned 7.4% over the past year.
Return vs Market: SKYE exceeded the US Market which returned 20.5% over the past year.
Price Volatility
| SKYE volatility | |
|---|---|
| SKYE Average Weekly Movement | 17.6% |
| Biotechs Industry Average Movement | 10.4% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: SKYE's share price has been volatile over the past 3 months.
Volatility Over Time: SKYE's weekly volatility has decreased from 26% to 18% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 11 | Punit Dhillon | skyebioscience.com |
Skye Bioscience, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes therapeutic drugs that modulate the endocannabinoid system. The company’s lead clinical program's product candidate is nimacimab, a peripherally-restricted negative allosteric modulating antibody specific for the human cannabinoid receptor 1 (CB1) receptor, administered as a subcutaneous injectable that is Phase II clinical trials for the treatment of metabolic disorders, including obesity. It is also developing SBI-100 Ophthalmic Emulsion,a CB1 agonist that is Phase II clinical trials for the treatment of glaucoma and ocular hypertension.
Skye Bioscience, Inc. Fundamentals Summary
| SKYE fundamental statistics | |
|---|---|
| Market cap | US$302.57m |
| Earnings (TTM) | -US$37.50m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-7.8x
P/E RatioIs SKYE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SKYE income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$37.50m |
| Earnings | -US$37.50m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.34 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 5.8% |
How did SKYE perform over the long term?
See historical performance and comparison